Kyverna Therapeutics, Inc. KYTX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $32.19M-43.4% | $124.09M+28.4% | $34.16M-67.4% | $53.44M-59.4% | $56.87M-74.6% | ||
| $204.25M+9.9% | $155.16M-18.1% | $136.97M-36.9% | $158.24M— | $185.78M— | ||
| $551K-1.1% | $551K-0.2% | $551K-2.3% | $551K— | $557K— | ||
| $15.42M-3.6% | $15.14M-9.3% | $16.06M+5.7% | $16.06M— | $16M— | ||
| $241.73M-2.4% | $282.95M-2.6% | $174.93M-46.2% | $214.33M— | $247.65M— | ||
| $1.34M-44.9% | $1.55M-53.8% | $1.79M-43.1% | $2.16M— | $2.44M— | ||
| $8.19M+42.1% | $3.57M-44.8% | $4.32M-39.6% | $5.05M— | $5.76M— | ||
| $5.01M+37.6% | $4.9M+72.9% | $5.36M+186% | $4.05M— | $3.64M— | ||
| $257.02M-1.4% | $293.83M-3.6% | $187.16M-44.8% | $226.51M— | $260.66M— | ||
| $29.84M+7.0% | $26.71M-0.6% | $26.03M-2.2% | $32.95M+91.8% | $27.89M+118% | ||
| $3.11M+1.1% | $9.99M+105% | $6.96M+56.8% | $4.97M— | $3.08M— | ||
| $221K-56.4% | $307K-60.6% | $190K-79.6% | $292K— | $507K— | ||
| $1.76M-42.7% | $3.66M+15.8% | $3.5M+16.5% | $3.28M— | $3.08M— | ||
| $221K-56.4% | $307K-60.6% | $190K-79.6% | $292K— | $507K— | ||
| $29.67M-10.9% | $36.49M+8.1% | $33.87M+9.3% | $39.79M— | $33.29M— | ||
| $6.96M+112% | $320K-92.3% | $1.33M-73.2% | $2.32M— | $3.28M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $0-100% | $0-100% | $8K-96.6% | $26K— | $73K— | ||
| $61.44M+67.7% | $61.55M+61.7% | $35.21M-3.5% | $42.13M— | $36.65M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $660.23M+24.1% | $657.01M+24.0% | $538.94M+2.0% | $534.63M— | $532.17M— | ||
| -$464.56M-50.8% | -$424.83M-61.2% | -$387.02M-71.2% | -$350.24M— | -$308.16M— | ||
| -$96K-9,500% | $97K-7.6% | $29K-81.0% | -$20K— | -$1K— | ||
| $195.58M-12.7% | $232.28M-12.9% | $151.95M-49.8% | $184.38M-44.7% | $224.01M-37.9% | ||
| $257.02M-1.4% | $293.83M-3.6% | $187.16M-44.8% | $226.51M— | $260.66M— | ||
| $204.25M+9.9% | $155.16M-18.1% | $136.97M-36.9% | $158.24M— | $185.78M— | ||
| $5.01M+37.6% | $4.9M+72.9% | $5.36M+186% | $4.05M— | $3.64M— | ||
| $8.19M+42.1% | $3.57M-44.8% | $4.32M-39.6% | $5.05M— | $5.76M— | ||
| $8.19M+42.1% | $3.57M-44.8% | $4.32M-39.6% | $5.05M— | $5.76M— | ||
| $5.01M+37.6% | $4.9M+72.9% | $5.36M+186% | $4.05M— | $3.64M— | ||
| $8.19M+42.1% | $3.57M-44.8% | $4.32M-39.6% | $5.05M— | $5.76M— | ||
| $5.01M+37.6% | $4.9M+72.9% | $5.36M+186% | $4.05M— | $3.64M— | ||
| $3.75M-40.0% | $3.75M-40.0% | $6.25M0.0% | $6.25M— | $6.25M— | ||
| $9.22M-22.5% | $13.47M-4.2% | $13.96M+117% | $15.08M— | $11.91M— | ||
| —— | —— | —— | —— | —— | ||
| $9.16M+32.1% | $4.6M-49.1% | $5.02M-50.1% | $5.92M— | $6.94M— | ||
| $660.23M+24.1% | $657.01M+24.0% | $538.94M+2.0% | $534.63M— | $532.17M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $221K-56.4% | $307K-60.6% | $190K-79.6% | $292K— | $507K— | ||
| $198K-67.2% | $305K-63.7% | $212K-80.3% | $366K— | $603K— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Kyverna Therapeutics, Inc.'s total assets?
- Kyverna Therapeutics, Inc. (KYTX) holds $257.0M in total assets, down 1.4% year over year.
- How much debt does Kyverna Therapeutics, Inc. have?
- Kyverna Therapeutics, Inc. carries $9.2M in total debt against $195.6M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does Kyverna Therapeutics, Inc. have?
- Kyverna Therapeutics, Inc. holds $32.2M in cash and equivalents.
- Can Kyverna Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.15 — current assets exceed current liabilities.
- Where does Kyverna Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.